FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

February 2012

Commission File Number – 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Name of Registrant)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Andhra Pradesh 500 034, India

+91-40-4900-2900

(Address of Principal Executive Offices)

Indicate by check mark whether registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F   þ            Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes   ¨             No   þ

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): ¨

Not applicable.

Table of Contents

(1) Press Release, “Dr. Reddy’s Q3 FY12 Financial Results,” February 3, 2012.

2

Press Release
	Dr. Reddy’s Laboratories Ltd.
	8-2-337, Road No. 3
	Banjara Hills, Hyderabad - 500 034
	Andhra Pradesh, India
	Tel: 91-40-4900-2900
	Fax: 91-40-4900-2999
	www.drreddys.com

DR. REDDY’S Q3 FY12 FINANCIAL RESULTS

Highest ever quarterly sales and profit

Hyderabad, India, February 3^rd, 2012: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter ended December 31, 2011 under International Financial Reporting Standards (IFRS).

Key Highlights

• Launch of olanzapine 20 mg (generic version of Eli Lilly’s Zyprexa^® 20 mg) in the US, another key milestone in consistently delivering limited competition opportunities

• Revenues for Q3 FY12 at `27.7 billion ($522 million), YoY growth of 46%

• Revenues for nine months FY12 at `70.2 billion ($1.3 billion), YoY growth of 29%

• EBITDA for Q3 FY12 at `9.2 billion ($174 million), 33% to sales, YoY growth of 127%

• EBITDA for nine months FY12 at `18.6 billion ($351 million), 27% to sales, YoY growth of 59%

• Adjusted* PAT for Q3 FY12 at `5.2 billion ($98 million), YoY growth of 91%

• Adjusted* PAT for nine months FY12 at `11.1 billion ($209 million), YoY growth of 44%

• Q3 FY12 g 33 new generic launches, 16 new generic filings and 7 DMF filings

* Note: Adjustments on account of interest on bonus debentures (net of tax)

3

All figures in millions, except EPS All US dollar figures based on convenience translation rate of 1USD = `53.01

Dr. Reddy’s Laboratories Limited and Subsidiaries

Unaudited Consolidated Income Statement

		September 30,			September 30,			September 30,			September 30,			September 30,			September 30,			September 30,
Particulars	Q3 FY12									Q3 FY11
	($)			(`)			%			($)			(`)			%			Growth %
Revenue		522			27,692			100			358			18,985			100			46
Cost of revenues		210			11,117			40			162			8,571			45			30
Gross profit		313			16,575			60			196			10,414			55			59
Operating Expenses
Selling, general & administrative expenses		145			7,679			28			120			6,374			34			20
Research and development expenses		29			1,514			5			25			1,306			7			16
Other operating (income) / expense		(3	)		(165	)		(1	)		(4	)		(199	)		(1	)		(17	)
Results from operating activities		142			7,547			27			55			2,933			15			157
Net finance (income) / expense		(3	)		(174	)		(1	)		1			48			0			—
Share of (profit) / loss of equity accounted investees		(0	)		(26	)		(0	)		0			1			0			—
Profit / (loss) before income tax		146			7,747			28			54			2,884			15			169
Income tax (benefit) / expense		49			2,616			9			3			152			1			—
Profit / (loss) for the period		97			5,131			19			52			2,732			14			88
Diluted EPS		0.6			30.2						0.3			16.1						88

Profit Computation

		September 30,		September 30,		September 30,		September 30,
	(in millions)
EBITDA Computation	Q3 FY12				Q3 FY11
	($)		(`)		($)		(`)
PBT (reported)		146		7,747		54		2,884
Interest		3		155		2		98
Depreciation		17		899		14		758
Amortization		8		408		6		307
EBITDA		174		9,208		76		4,048

		September 30,		September 30,		September 30,		September 30,
	(in millions)
Adjusted PAT Computation	Q3 FY12				Q3 FY11
	($)		(`)		($)		(`)
PAT (reported)		97		5,131		52		2,732
Adjustments:
Interest on Bonus Debentures (net of tax)		1		78
Adjusted PAT		98		5,209		52		2,732

4

Key Balance Sheet Items

		September 30,		September 30,		September 30,		September 30,
	(in millions)
Particulars	As on 31st Dec 11				As on 30th Sep 11
	($)		(`)		($)		(`)
Cash and cash equivalents		313		16,587		143		7,596
Trade receivables		498		26,373		388		20,568
Inventories		369		19,586		351		18,592
Property, plant and equipment		612		32,433		593		31,450
Goodwill and Other Intangible assets		287		15,182		285		15,115
Loans and borrowings (current & non-current)		727		38,502		591		31,303
Trade payables		173		9,189		169		8,940
Equity		980		51,927		907		48,081

Q3 FY12 Revenue Mix by Segment

		September 30,		September 30,		September 30,		September 30,		September 30,		September 30,		September 30,
	(in millions)
	Q3 FY12						Q3 FY11						Growth %
	($)		(`)		%		($)		(`)		%
Global Generics		402		21,287		77		256		13,589		72		57
North America				11,114						4,765				133
Europe				2,426						2,124				14
India				3,333						3,000				11
Russia & Other CIS				3,317						2,880				15
RoW				1,097						820				34
PSAI		105		5,563		20		94		4,979		26		12
North America				1,170						770				52
Europe				1,651						1,830				(10	)
India				862						622				39
RoW				1,880						1,757				7
Others		15		842		3		8		417		2		102
Total		522		27,692		100		358		18,985		100		46

Q3 FY12 Revenue Mix by Geography

		September 30,		September 30,		September 30,		September 30,		September 30,		September 30,		September 30,
	(in millions)
	Q3 FY12						Q3 FY11						Growth %
	($)		(`)		%		($)		(`)		%
North America		242		12,826		46		110		5,823		31		120
Europe		82		4,325		16		77		4,078		21		6
India		79		4,194		15		68		3,625		19		16
Russia & Other CIS		63		3,317		12		54		2,880		15		15
Others		56		3,030		11		49		2,579		14		17
Total		522		27,692		100		358		18,985		100		46

5

SEGMENTAL ANALYSIS

Global Generics: North America

Revenues from North America were at `11.1 billion in Q3 FY12 versus `4.8 billion in Q3 FY11. Growth was led by the high value launch of olanzapine 20 mg, new products launched in the last twelve months and strong volume growth across key products.

• 2 new products launched during the quarter – olanzapine 20 mg and olanzapine ODT.

• Strong volume growth contributed by key products such as lansoprazole, tacrolimus, omeprazole Mg OTC and Shreveport products and last twelve months new launches of fondaparinux and antibiotics portfolio.

• 26 prescription products feature among the Top 3 in market share (Source: IMS Volumes November 2011).

• During the quarter, 3 ANDAs were filed. The cumulative ANDA filings as of 31^st December, 2011 are 187. A total of 79 ANDAs are pending for approval with the USFDA of which 40 are Para IVs and 10 are FTFs.

Global Generics: Russia & Other CIS

Revenues in Russia & Other CIS markets were at `3.3 billion in Q3 FY12 versus `2.9 billion in Q3 FY11.

• Revenues in Russia were at `2.8 billion in Q3 FY12.

• The company’s secondary sales growth at 23% continued to outperform industry’s growth of 19%. (Source: Pharmexpert Prescription Sales November 2011).

• Top 5 products feature among Top 2 ranks in market share.

• OTC portfolio grew by 24% over previous year.

• Revenues in Other CIS markets were at `557 million in Q3 FY12; year-on-year growth driven largely by Ukraine and Kazakhstan.

Global Generics: India

Revenues in India were at `3.3 billion in Q3 FY12 versus `3.0 billion in Q3 FY11, driven by volume increase in key products and new product launches in the last twelve months.

• 6 new products launched during the quarter.

• Biosimilars portfolio grew by 25% over previous year.

Global Generics: Europe

Revenues from Europe were at `2.4 billion in Q3 FY12 versus `2.1 billion in Q3 FY11.

• Revenues from Germany were at `1.5 billion in Q3 FY12. Growth in new product launches outside the scope of tender was offset by price erosion in products within tenders.

• Revenues from Rest of Europe were at `881million.

Pharmaceutical Services and Active Ingredients (PSAI)

Revenues from PSAI were at `5.6 billion in Q3 FY12 versus `5.0 billion in Q3 FY11. Growth was largely driven by Pharmaceutical Services segment and benefit of rupee depreciation.

• During the quarter, 7 DMFs were filed globally including 2 in US, 2 in Europe and 3 in rest of the markets. The cumulative DMF filings as of 31^st December 2011 are 513 globally.

6

INCOME STATEMENT HIGHLIGHTS:

• Gross profit margin 60% to revenues in Q3 FY12, increased largely on account of a favorable mix of high margin olanzapine revenues and benefit of rupee depreciation.

• Selling, General & Administration (SG&A) expenses including amortization at `7.7 billion ($145 million) increased by 20% over Q3 FY11. This increase is on account of higher manpower and freight costs and the effect of rupee depreciation against multiple currencies.

• Net Finance income at `174 million ($3 million) in Q3 FY12 versus net Finance cost of `49 million ($1 million) in Q3 FY11. The change is on account of :

• Net forex gain of `285 million ($5 million) in Q3 FY12 versus net forex loss of `45 million ($1 million) in Q3 FY11.

• Net interest expense of `155 million ($3 million) in Q3 FY12 versus `98 million ($2 million) in Q3 FY11.

• Profit on sale of investments of `44 million ($1 million) in Q3 FY12 versus `4 million in Q3 FY11.

• EBITDA of `9.2 billion ($174 million) in Q3 FY12, represents 33% of revenues and recorded a year-on-year growth of 127%. EBITDA of `18.6 billion ($351 million) for nine months ended December 2011, represents 27% of revenues and recorded a year-on-year growth of 59%.

• Profit after Tax adjusted for interest on bonus debentures (net of tax), was at `5.2 billion ($98 million) in Q3 FY12, 19% of revenues and year-on-year growth of 91%. Adjusted PAT for nine months ended December 2011 was `11.1 billion ($209 million) and recorded year-on-year growth of 44%.

• Adjusted EPS for Q3 FY12 was `30.6 ($0.6) versus `16.1 ($0.3) in Q3 FY11. Adjusted EPS for nine months ended December 2011 was `65.1 ($1.2).

• Capital expenditure for nine months ended December 2011, was `5.0 billion ($94 million).

7

Consolidated Income Statement: Nine months ending December 2011

All figures in millions, except EPS All US dollar figures based on convenience translation rate of 1USD = `53.01

		September 30,			September 30,			September 30,			September 30,			September 30,			September 30,			September 30,
	9 Months FY12									9 Months FY11
Particulars	($)			(`)			%			($)			(`)			%			Growth %
Revenue		1,323			70,153			100			1,028			54,520			100			29
Cost of revenues		581			30,818			44			475			25,206			46			22
Gross profit		742			39,335			56			553			29,314			54			34
Operating Expenses
Selling, general & administrative expenses		409			21,651			31			331			17,562			32			23
Research and development expenses		79			4,170			6			67			3,569			7			17
Other operating (income) / expense		(11	)		(567	)		(1	)		(11	)		(602	)		(1	)		(6	)
Results from operating activities		266			14,081			20			166			8,786			16			60
Net finance (income) / expense		(1	)		(78	)		(0	)		5			262			0			—
Share of (profit) / loss of equity accounted investees		(1	)		(43	)		(0	)		(0	)		(7	)		(0	)		514
Profit / (loss) before income tax		268			14,202			20			161			8,531			16			66
Income tax (benefit) / expense		63			3,366			5			16			836			2			303
Profit / (loss) for the period		204			10,836			15			145			7,695			14			41
Diluted EPS		1.2			63.7						0.9			45.3						41

Profit Computation

		September 30,		September 30,		September 30,		September 30,
	(in millions)
EBITDA Computation	9 Months FY12				9 Months FY11
	($)		(`)		($)		(`)
PBT (reported)		268		14,202		161		8,531
Interest		11		601		2		95
Depreciation		49		2,606		41		2,174
Amortization		23		1,202		17		912
EBITDA		351		18,611		221		11,712

		September 30,		September 30,		September 30,		September 30,
	(in millions)
Adjusted PAT Computation	9 Months FY12				9 Months FY11
	($)		(`)		($)		(`)
PAT (reported)		204		10,836		145		7,695
Adjustments:
Interest on Bonus Debentures (net of tax)		5		235
Adjusted PAT		209		11,071		145		7,695

8

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three business segments—Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Focus markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, Australia and New Zealand.

For more information, log on to: www.drreddys.com

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

CONTACT INFORMATION

Investors and Financial Analysts:

Kedar Upadhye at kedaru@drreddys.com or on +91-40-66834297

Raghavender R at raghavenderr@drreddys.com or on +91-40-49002135

Milan Kalawadia (North America) at mkalawadia@drreddys.com or on +1-9082034931

Media:

Rajan S at rajans@drreddys.com or on +91-40-49002445

Note: All discussions in this release are based on unaudited consolidated IFRS financials.

9

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
	By:	/s/ Sandeep Poddar
Date: February 6, 2012		Name: Sandeep Poddar
		Title: Company Secretary

10